Canine lymphoma is the most common hematopoietic neoplasm in dogs, arising from monoclonal expansion of B lymphocytes, T lymphocytes, or null cells (non-B and non-T, natural killer cells - NK). It might originate in any area of the body and its most striking feature is its heterogeneity, accounting for more than 30 different subtypes. Novel entities have recently been described and characterized in canine medicine, such as diffuse small B-cell lymphoma and small cell T cell intestinal lymphoma, to list a few. Despite extensive studies, recent progression in therapeutical approaches and improved outcomes, relapse or recurrence remain a common problem with conventional therapy for intermediate/high grade lymphomas, in contrast with indolent ones that are generally characterized by a fairer outcome.
In light of the aforementioned considerations, differentiation among different subtypes is essential for predicting behavior and determining adequate treatment and this still largely relies on immunophenotyping through immunohistochemistry (IHC), flow cytometry, and polymerase chain reaction (PCR) for antigen receptor rearrangements (PARR). Paralleling these techniques, molecular biomarkers MicroRNAs (miRNAs) for accurate and rapid diagnosis are developing, together with blood-based liquid biopsies detecting circulating tumor DNA. We aim to showcase new insights into canine lymphoma pathogenesis, biology, early diagnosis, prognosis, clinical-pathological features and therapeutic approaches. To do this we strongly encourage contributions from veterinary oncologists, radiologists, pathologists, immunologists and geneticists to get a comprehensive approach to this entity. The aim of this Research Topic is to provide an overview on tools currently available in pathogenesis, diagnosis, prognosis and treatment and give insights of new advances in canine lymphoma with a comparative oncology perspective.
Submissions that focus on the following are highly encouraged:
- Novel canine lymphoma diagnostic tools (e.g. enabling early tumor detection);
- The treatment of canine lymphoma with novel therapeutic approaches exploiting immune- or targeted therapy;
- The molecular and biological pathways driving tumor development and multicentric dissemination of canine lymphoma;
- Novel insights on the epidemiology and risk factors of canine lymphoma;
- Comparative studies on the similarities and differences between canine and lymphoma in humans or other species;
- Advances in canine lymphoma staging (including evaluation of prognostic factors);
- Study of paraneoplastic syndromes associated with canine lymphoma.
With regards to methodological approaches, we will welcome articles that include:
- Cytology and immunocytochemistry;
- Histopathology and immunohistochemistry;
- Clonality testing (PARR);
- Flow cytometry;
- Molecular landscape and gene analysis;
- Animal model characterization;
- Biomarker discovery and validation;
- Diagnostic imaging;
- Surgical approaches.
Vittoria Castiglioni is an employee for IDEXX Laboratories (Germany) and Sabina Soldati is an Associate in Pathology Experts GmbH.
Canine lymphoma is the most common hematopoietic neoplasm in dogs, arising from monoclonal expansion of B lymphocytes, T lymphocytes, or null cells (non-B and non-T, natural killer cells - NK). It might originate in any area of the body and its most striking feature is its heterogeneity, accounting for more than 30 different subtypes. Novel entities have recently been described and characterized in canine medicine, such as diffuse small B-cell lymphoma and small cell T cell intestinal lymphoma, to list a few. Despite extensive studies, recent progression in therapeutical approaches and improved outcomes, relapse or recurrence remain a common problem with conventional therapy for intermediate/high grade lymphomas, in contrast with indolent ones that are generally characterized by a fairer outcome.
In light of the aforementioned considerations, differentiation among different subtypes is essential for predicting behavior and determining adequate treatment and this still largely relies on immunophenotyping through immunohistochemistry (IHC), flow cytometry, and polymerase chain reaction (PCR) for antigen receptor rearrangements (PARR). Paralleling these techniques, molecular biomarkers MicroRNAs (miRNAs) for accurate and rapid diagnosis are developing, together with blood-based liquid biopsies detecting circulating tumor DNA. We aim to showcase new insights into canine lymphoma pathogenesis, biology, early diagnosis, prognosis, clinical-pathological features and therapeutic approaches. To do this we strongly encourage contributions from veterinary oncologists, radiologists, pathologists, immunologists and geneticists to get a comprehensive approach to this entity. The aim of this Research Topic is to provide an overview on tools currently available in pathogenesis, diagnosis, prognosis and treatment and give insights of new advances in canine lymphoma with a comparative oncology perspective.
Submissions that focus on the following are highly encouraged:
- Novel canine lymphoma diagnostic tools (e.g. enabling early tumor detection);
- The treatment of canine lymphoma with novel therapeutic approaches exploiting immune- or targeted therapy;
- The molecular and biological pathways driving tumor development and multicentric dissemination of canine lymphoma;
- Novel insights on the epidemiology and risk factors of canine lymphoma;
- Comparative studies on the similarities and differences between canine and lymphoma in humans or other species;
- Advances in canine lymphoma staging (including evaluation of prognostic factors);
- Study of paraneoplastic syndromes associated with canine lymphoma.
With regards to methodological approaches, we will welcome articles that include:
- Cytology and immunocytochemistry;
- Histopathology and immunohistochemistry;
- Clonality testing (PARR);
- Flow cytometry;
- Molecular landscape and gene analysis;
- Animal model characterization;
- Biomarker discovery and validation;
- Diagnostic imaging;
- Surgical approaches.
Vittoria Castiglioni is an employee for IDEXX Laboratories (Germany) and Sabina Soldati is an Associate in Pathology Experts GmbH.